This study assesses whether the MGMT protein expression in patients with late-stage gastric cancer is associated with prognosis or the need for fluorouracil-based adjuvant chemotherapy.
This study analyzes patient and tumor characteristics to create a model that can predict survival benefits from adjuvant chemotherapy among patients with stage II or stage III gastric cancer.
This retrospective review of data indicates that the survival outcome in patients undergoing surgery for gastric cancer is associated with lymph node count rather than with cancer program classification.
Brar et al define optimal treatment strategies for gastric adenocarcinoma. See also the invited commentary by Schulick.
You currently have no searches saved.